Back to results
US 2021/0196705 A1Published application
Bupropion as a modulator of drug activity
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Claims20
A method of increasing dextromethorphan plasma levels, comprising co-administering bupropion and dextromethorphan once a day or twice a day for at least 8 consecutive days to a human being who is a non-poor metabolizer of dextromethorphan in need of treatment with dextromethorphan;
- wherein about 50 mg to about 220 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, is co-administered with about 40 mg to about 60 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan, once a day or twice a day;
- and wherein co-administering the bupropion and the dextromethorphan results in an AUC0-24 of dextromethorphan on the eighth day that is about 20 times to about 1,000 times the AUC0-24 that would result from administering 60 mg of dextromethorphan hydrobromide without bupropion for eight consecutive days.
Dependencies are inferred from the claim text.